Skip to main content

Translation of novel Biomarkers for Bladder Cancer for clinical outcome prediction

Objective

Currently, clinical diagnosis and monitoring of bladder cancer (BC) relies on invasive, highly costly cystoscopy. Additionally, due to high recurrence rates BC treatment is associated with frequent follow-up of patients, making BC one of the most costly types of cancer in terms of management cost. Thus there is a clear clinical need for the development of new approaches for early detection of recurrence and progression.
Our proposal is based on the identification of novel biomarkers (BM) for BC recurrence and progression in urine and powerful technological platforms as extensive foreground work of the involved partners in the framework of FP7 EU projects DECanBio and GENINCA. The objective of TransBioBC is to translate this foreground work in the field of BC and to specifically employ the involved technologies (CE-MS and micro-ELISA), represented by the participating SMEs, for the development of non-invasive urine tests for routine monitoring of BC recurrence and progression. Our project uniquely integrates leading BC clinical experts with experts on proteome analysis and high throughput immunoassay development in an implementation-oriented workflow. Strict monitoring of assay analytical performance, and properly collected and well characterized clinical samples from existing sufficiently powered BC cohorts are combined with in-depth knowledge of regulatory requirements, analysis approaches to define added value and well designed business plans including multi-stakeholder dissemination and exploitation plans.
Collectively, TransBioBC will provide strong evidence for utility of the new BM directly in BC clinical management and as a secondary aim for usage in clinical trials and drug development.

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer/bladder cancer
  • /social sciences/economics and business
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins/proteomics

Call for proposal

FP7-HEALTH-2013-INNOVATION-2
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Address
Soranou Efesiou 4
115 27 Athina
Greece
Activity type
Research Organisations
EU contribution
€ 760 964,80
Administrative Contact
Dimitris Raptis (Mr.)

Participants (3)

MOSAIQUES DIAGNOSTICS GMBH
Germany
EU contribution
€ 1 119 089
Address
Rotenburger Strasse 20
30659 Hannover
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Harald Mischak (Prof.)
DIAGNOSWISS SA
Switzerland
EU contribution
€ 831 344
Address
Zi Les Ilettes Secteur 4
1870 Monthey
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Frédéric Reymond (Dr.)
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Spain
EU contribution
€ 548 960,80
Address
Calle Melchor Fernandez Almagro 3
28029 Madrid
Activity type
Research Organisations
Administrative Contact
Lilit Manukyan (Ms.)